A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Healthy Volunteers Clinical Trial

Official title:

A Phase 0, Open-label, Candidate Selection Study Assessing the Pharmacokinetics of 3 Drug Candidates After a Single Intravenous, 14C-labelled Microdose in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04676906
• Other study ID #: NN9520-4709
• Secondary ID: 2020-003449-13U1
• Status: Completed
• Phase: Phase 1
• Start date: November 26, 2020
• Est. completion date: April 28, 2021

Study information

• Verified date: April 2023
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

People with type 2 diabetes have too much sugar in their blood and need treatment to control their sugar level. The 3 study compounds in this study are similar to an approved antidiabetic medicine that helps to lower blood sugar levels in people with type 2 diabetes. This approved antidiabetic medicine is generally safe and well tolerated. The study compounds are expected to have the same antidiabetic effect as the approved medicine. The purpose of this study is to investigate how quickly and to what extent each of the 3 study compounds are broken down in the body (this is called pharmacokinetics). The dose of each study compound will be very low (this is called a microdose), and will be labelled with a small amount of carbon-14. This is radioactive, and it makes it possible to track the study compound in the blood. The 3 study compounds in this study have not been given to humans before. The study will be performed in up to 18 healthy male volunteers. The study will consist of 3 groups of 6 volunteers each. Each participant will receive only one dose of study medicine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: April 28, 2021
• Est. primary completion date: April 28, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 54 Years

Eligibility

Inclusion Criteria:

• Healthy subject.

• Sex : Male.

• Age 18 to 54 years, inclusive, at the time of signing informed consent.

• Body mass index (BMI) 18.0 to 30.0 kg/m^2, inclusive, at the time of signing informed consent .

Exclusion Criteria:

• Known or suspected hypersensitivity to study product(s) or related products.

• Any disorder that in the Investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol.

• Glycosylated haemoglobin (HbA1c) equal to or above 6.5% (48 mmol/mol) at screening.

• Personal or first-degree relative(s) history of multiple endocrine neoplasia Type 2 or medullary thyroid carcinoma.

• Subjects with a history of malignant neoplasms within the past 5 years prior to screening.

• Presence or history of pancreatitis (acute or chronic; as declared by the subject or reported in the medical records).

• Participation in a study with a radiation burden of above 0.1 millisievert (mSv) in the period of 1 year prior to screening.

Related Conditions & MeSH terms

• Healthy Volunteers
• Type 2 Diabetes

Intervention

Drug:
• NNC0113-6861
Study compound 1 - Each participant will receive a single intravenous (i.v) dose of [14C]-NNC0113-6861
• NNC0113-6860
Study compound 2 - Each participant will receive a single i.v dose of [14C]-NNC0113-6860
• NNC0113-6891
Study compound 3 - Each participant will receive a single i.v dose of [14C]-NNC0113-6891

Locations

Country	Name	City	State
Netherlands	Novo Nordisk Investigational Site	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds	hours	From time of first dosing (Day 1) until Day 64